EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling

Sven O Göpel, Damilola Adingupu, Jue Wang, Elizaveta Semenova, Margareta Behrendt, Rasmus Jansson-Löfmark, Christine Ahlström, Ann-Cathrine Jönsson-Rylander, V Sashi Gopaul, Russell Esterline, Li-Ming Gan, Rui-Ping Xiao

Cardiovascular Diabetology · 2024

DOI: 10.1186/s12933-024-02491-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Diabetology, 2024. Verfasst von Sven O Göpel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden. Sven.gopel@astrazeneca.com. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon, Signal Transduction, Glucosides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i’s produce a unique metabolic pattern by lowering blood glucose without increasing insulin while increasing ketone body and glucagon levels and reducing body weight. We tested if glucagon signaling contributes to SGLT2i induced improvement in CV function.

Methods

Cardiac contractility and coronary flow velocity reserve (CFVR) were monitored in ob/ob mice and rhesus monkeys with metabolic syndrome using echocardiography. Metabolic status was characterized by measuring blood ketone levels, glucose tolerance during glucose challenge and Arg and ADMA levels were measured. Baysian models were developed to analyse the data.

Results

Dapagliflozin improved CFVR and contractility, co-application of a glucagon receptor inhibitor (GcgRi) blunted the effect on CFVR but not contractility. Dapagliflozin increased the Arg/ADMA ratio and ketone levels and co-treatment with GcgRi blunted only the Dapagliflozin induced increase in Arg/ADMA ratio but not ketone levels.

Conclusions

Since GcgRi co-treatment only reduced the Arg/ADMA increase we hypothesize that dapagliflozin via a glucagon-signaling dependent pathway improves vascular function through the NO-signaling pathway leading to improved vascular function. Increase in ketone levels might be a contributing factor in SGLT2i induced contractility increase and does not require glucagon signaling. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucagonSignal TransductionGlucosidesBenzhydryl CompoundsArginineMyocardial ContractionDisease Models, AnimalMacaca mulattaAnimalsMaleMice, Inbred C57BLBlood GlucoseMetabolic SyndromeKetone BodiesBiomarkersBlood Flow VelocityCoronary VesselsSodium-Glucose Transporter 2

Stichwörter der Autor:innen

Argenine/ADMA ratioCardiac contractilityCoronary flow velocity reserveEchocardiographyGlucagonHeart failureMetabolic syndromeSGLT2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagondapagliflozinGlucosidesBenzhydryl CompoundsArginineN,N-dimethylarginineBlood GlucoseSlc5a2 protein, mouseKetone Bodies

Autor:innen und Institutionen

  • Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden. Sven.gopel@astrazeneca.com.
  • Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • College of Future Technology, Peking University, Beijing, 100871, China.
  • Data Sciences and Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London, United Kingdom.
  • Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Förderung

  • AstraZeneca

Zitieren

APA

Göpel, S. O., Adingupu, D., Wang, J., Semenova, E., Behrendt, M., Jansson-Löfmark, R., Ahlström, C., Jönsson-Rylander, A. C., Gopaul, V. S., Esterline, R., Gan, L. M., & Xiao, R. P. (2024). SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-024-02491-w

Vancouver

Göpel SO, Adingupu D, Wang J, Semenova E, Behrendt M, Jansson-Löfmark R, et al. SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling. Cardiovascular Diabetology. 2024. doi:10.1186/s12933-024-02491-w

BibTeX
@article{Gpel2024,
  author = {Göpel, Sven O and Adingupu, Damilola and Wang, Jue and Semenova, Elizaveta and Behrendt, Margareta and Jansson-Löfmark, Rasmus and Ahlström, Christine and Jönsson-Rylander, Ann-Cathrine and Gopaul, V Sashi and Esterline, Russell and Gan, Li-Ming and Xiao, Rui-Ping},
  title = {SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling},
  journal = {Cardiovascular Diabetology},
  year = {2024},
  doi = {10.1186/s12933-024-02491-w}
}
Kostenlos starten →